Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Strebhardt

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Nature Reviews. Drug Discovery|July 31, 2010
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapyKlaus Strebhardt
Cell Cycle (Georgetown, Tex.)|June 2, 2015
Drugging Plk1: An attractive approach to inhibit androgen receptor signalingKlaus Strebhardt
ACS Chemical Biology|December 23, 2006
Small molecules keep mitotic kinases in checkKlaus Strebhardt
Nature Reviews. Cancer|May 13, 2008
Paul Ehrlich's magic bullet concept: 100 years of progressKlaus Strebhardt, Axel Ullrich
Current Pharmaceutical Design|October 28, 2005
RNA interference-based gene silencing in mice: the development of a novel therapeutical strategyBirgit Spänkuch, Klaus Strebhardt
Cancer Research|July 20, 2006
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysisFrank Eckerdt, Klaus Strebhardt
The New England Journal of Medicine|December 8, 2006
Another look at imatinib mesylateKlaus Strebhardt, Axel Ullrich
Cell Research|September 18, 2013
Plk1: unexpected roles in DNA replicationRanadip Mandal, Klaus Strebhardt
Nature Reviews. Cancer|March 25, 2006
Targeting polo-like kinase 1 for cancer therapyKlaus Strebhardt, Axel Ullrich
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Polo-like kinase 1: target and regulator of transcriptional controlBernd T Martin, Klaus Strebhardt
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Nature Reviews. Drug Discovery|July 31, 2010
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapyKlaus Strebhardt
Cell Cycle (Georgetown, Tex.)|June 2, 2015
Drugging Plk1: An attractive approach to inhibit androgen receptor signalingKlaus Strebhardt
ACS Chemical Biology|December 23, 2006
Small molecules keep mitotic kinases in checkKlaus Strebhardt
Nature Reviews. Cancer|May 13, 2008
Paul Ehrlich's magic bullet concept: 100 years of progressKlaus Strebhardt, Axel Ullrich
Current Pharmaceutical Design|October 28, 2005
RNA interference-based gene silencing in mice: the development of a novel therapeutical strategyBirgit Spänkuch, Klaus Strebhardt
Cancer Research|July 20, 2006
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysisFrank Eckerdt, Klaus Strebhardt
The New England Journal of Medicine|December 8, 2006
Another look at imatinib mesylateKlaus Strebhardt, Axel Ullrich
Cell Research|September 18, 2013
Plk1: unexpected roles in DNA replicationRanadip Mandal, Klaus Strebhardt
Nature Reviews. Cancer|March 25, 2006
Targeting polo-like kinase 1 for cancer therapyKlaus Strebhardt, Axel Ullrich
Cell Cycle (Georgetown, Tex.)|December 19, 2006
Polo-like kinase 1: target and regulator of transcriptional controlBernd T Martin, Klaus Strebhardt
Pageof 11